Atossa Therapeutics (Nasdaq:ATOS) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ATOS Stoklara Genel Bakış

ATOS temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 99.1% daha düşük bir oranda işlem görüyor

Kazançların yılda 71.1% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Atossa Therapeutics, Inc. Rakipler

Graphite Bio

NasdaqGM:GRPH

US$190.4m

Vaxart

NasdaqCM:VXRT

US$186.8m

Greenwich LifeSciences

NasdaqCM:GLSI

US$179.6m

Shattuck Labs

NasdaqGS:STTK

US$61.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Atossa Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.47
52 Haftanın En Yüksek Seviyesi	US$2.31
52 Haftanın En Düşük Seviyesi	US$0.62
Beta	1.2
11 Aylık Değişim	8.09%
3 Aylık Değişim	34.86%
1 Yıllık Değişim	102.90%
33 Yıllık Değişim	-53.77%
5 Yıllık Değişim	-13.02%
Halka arzdan bu yana değişim	-99.83%

Son Haberler & Güncellemeler

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Jul 01

Recent updates

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Jul 01

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Mar 07

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Nov 08

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Apr 26

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

May 12

A First Assessment On Atossa Therapeutics

Dec 10

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 02

Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World

Sep 22

Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business

Jul 17

Atossa Therapeutics: Hope Springs Eternal

Jun 30

Atossa Therapeutics to be included in the Russell 2000, 3000 indexes

Jun 16

Atossa reaches a two-year high ahead of data readout for breast cancer therapy

Jun 07

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Apr 02

Atossa updates on single-patient study for Endoxifen

Feb 04

Atossa halts Endoxifen breast cancer study after positive data

Feb 02

Atossa Therapeutics prices ~$25M direct offering, stock -23% PM

Jan 06

Atossa Therapeutics prices $14M registered direct offering

Dec 17

We're A Little Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Dec 10

Atossa Therapeutics plummets 38% after it raises $20M in public offering

Dec 09

Atossa Therapeutics EPS in-line

Nov 13

Safety data on COVID-19 nasal spray fails to lift Atossa, down 6%

Nov 10

Hissedar Getirileri

	ATOS	US Biotechs	US Pazar
7D	-2.6%	-0.5%	0.3%
1Y	102.9%	18.0%	32.4%

Getiri vs. Endüstri: ATOS geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: ATOS geçen yıl % 34.1 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is ATOS's price volatile compared to industry and market?
ATOS volatility
ATOS Average Weekly Movement	8.7%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ATOS son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ATOS 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2008	12	Steve Quay	www.atossatherapeutics.com

Klinik aşamalı bir biyofarmasötik şirketi olan Atossa Therapeutics, Inc. onkolojide karşılanmamış tıbbi ihtiyaç alanlarında kadın meme kanseri ve Amerika Birleşik Devletleri'ndeki diğer durumlar için ilaçlar geliştirmektedir. Şirketin öncü ilaç adayı, meme kanserini tedavi etmek ve önlemek için Faz II klinik çalışmalarında olan tamoksifenin aktif bir metaboliti olan oral (Z)-endoksifendir. Şirket ayrıca immünoterapi/kimerik antijen reseptör terapi programları da geliştirmektedir.

Atossa Therapeutics, Inc. Temel Bilgiler Özeti

Atossa Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ATOS temel i̇stati̇sti̇kler
Piyasa değeri	US$177.32m
Kazançlar(TTM)	-US$25.91m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-7.1x

F/K Oranı

ATOS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ATOS gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$25.91m
Kazançlar	-US$25.91m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.21
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

ATOS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ATOS Stoklara Genel Bakış

Ödüller

Risk Analizi

Atossa Therapeutics, Inc. Rakipler

NasdaqGM:GRPH

US$190.4m

NasdaqCM:VXRT

US$186.8m

NasdaqCM:GLSI

US$179.6m

NasdaqGS:STTK

US$61.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Recent updates

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

No longer forecast to breakeven

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

New minor risk - Profitability

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for A U.S. Breast Cancer Patient

New minor risk - Share price stability

Atossa Therapeutics Regain Compliance with Nasdaq Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Less than half of directors are independent

Atossa Therapeutics Appoints Tessa Cigler to Its Board of Directors

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

Atossa Therapeutics, Inc. Announces First Patient Dosed with Selective Estrogen Receptor Modulator in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Forecast to breakeven in 2026

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Atossa Therapeutics, Inc. Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

Atossa Therapeutics, Inc. Appoints Jonathan Finn to Its Board of Directors

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group

Atossa Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Insufficient new directors

Atossa Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Atossa Therapeutics, Inc. Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

New minor risk - Share price stability

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) announces an Equity Buyback for $10 million worth of its shares.

Atossa Therapeutics, Inc. Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Announces Executive Changes

Price target decreased by 7.5% to US$4.63

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

Price target decreased to US$5.00

Price target decreased to US$5.00

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. (NasdaqCM:ATOS) agreed to acquire 19.99% equity in Dynamic Cell Therapies, Inc. for $5 million.

Atossa Therapeutics, Inc. Appoints Richard Graydon as Interim Chief Medical Officer

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate Its Phase 2 Study of Neoadjuvant (Z)-Endoxifen in Premenopausal Women with Er+/Her2- Breast Cancer

Atossa Therapeutics: Still Gets An 'Incomplete' Rating

Atossa Therapeutics Receives Letter from NASDAQ Regarding Minimum Bid Price Requirement

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

Atossa Therapeutics, Inc. Appoints Dr. Paul Wabnitz to its Scientific Advisory Board

Atossa Therapeutics GAAP EPS of -$0.05

Atossa Therapeutics, Inc. Announces Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Insufficient new directors

Atossa Therapeutics, Inc. Announces Completion of Participants Enrollment in Part B of its Phase 1/2a Clinical Study of AT-H201 in Australia, Consisting of Multiple Ascending Dose Cohorts in Healthy Participants

Atossa Therapeutics, Inc., Annual General Meeting, May 13, 2022

No longer forecast to breakeven